Published online 26 March 2008
Haematologica, Vol 93, Issue 5, 761-764 doi:10.3324/haematol.10985
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spinowitz, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spinowitz, B. S.

Anemia of Renal Failure

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta}

Bruce S. Spinowitz

New York Hospital, Queens, Cornell University Medical Center, New York, NY, USA

Correspondence: Bruce S. Spinowitz, M.D. FACP, Associate Director, Nephrology, Associate Chairman, Medicine, New York Hospital, Queens, Clinical Professor of Medicine, Cornell University Medical Center, New York, NY, USA. E-mail: bss9001{at}nyp.org

In a one-year, multicenter, open-label, uncontrolled trial, epoetin {delta} was given subcutaneously, 1–3-times weekly to peritoneal dialysis patients who had previously received an epoetin. Dose was adjusted to maintain hemoglobin at 10.0–12.0 g/dL. The primary endpoint was mean hemoglobin over weeks 12–24. Safety was assessed. Mean±SD baseline hemoglobin was 11.2±0.9 g/dL. Hemoglobin over weeks 12–24 was 11.6±1.1 g/dL. Adverse events were those expected in this patient population. No life-threatening adverse events occurred. Subcutaneous epoetin {delta} was effective and well tolerated for the treatment of anemia in peritoneal dialysis patients.

Key words: anemia, peritoneal dialysis, epoetin.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek, R. Vanholder, and on behalf of the ERA-EDTA ERBP Advisory Board
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 348 - 354.
[Full Text] [PDF]